Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study
Files
Publication date
2019-08
Authors
Plesner, Torben
Arkenau, Hendrik-Tobias
Gay, Francesca
Minnema, Monique
Boccadoro, Mario
Moreau, Philippe
Cavenagh, Jamie
Perrot, Aurore
Laubach, Jacob P.
Krejcik, Jakub
Editors
Advisors
Supervisors
Document Type
Letter
Metadata
Show full item recordCollections
License
taverne
Abstract
Keywords
daratumumab, monoclonal antibody, multiple myeloma, relapsed/refractory multiple myeloma, plasma cell disorders, Taverne, Hematology
Citation
Plesner, T, Arkenau, H-T, Gay, F, Minnema, M C, Boccadoro, M, Moreau, P, Cavenagh, J, Perrot, A, Laubach, J P, Krejcik, J, Ahmadi, T, de Boer, C, Chen, D, Chiu, C, Schecter, J M & Richardson, P G 2019, 'Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study', British Journal of Haematology, vol. 186, no. 3, pp. E35-E39. https://doi.org/10.1111/bjh.15879